pulmonary squamous-cellcarcinoma
Conditions
Interventions
to evaluate the outcomes including PFS in the chemotherapy cosisting of cisplatin, gemcitabine and docetaxel
Sponsors
Okayama Lung Cancer Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: pathologically proven squamous cell carcinoma stage IV or stage III without suitability for curative treatment aged 20 or older measurable tumor sites no prior chemotherapy no prior systemic anticancer therapy including palliative brain or bone irradiation within 2 weeks of proposed entry to this trial ECOG PS of 0 to 1 appropriate organ function acquisition of written informed consent
Exclusion criteria
Exclusion criteria: pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with active other cancers pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pts with symptomatic brain metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate primarily PFS of the doublet chemotherapy (cisplatin and gemcitabine) and maintenance chemotherapy (docetaxel) | — |
Countries
Japan
Contacts
Public ContactKatsuyuki Hotta
Okayama University Hospital Department of Respiratory Medicine
Outcome results
None listed